Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 278

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas

Open access
Appay, Romain, Dehais, Caroline, Maurage, Claude-Alain, Alentorn, Agusti, Carpentier, Catherine, Colin, Carole, Ducray, François, Escande, Fabienne, Idbaih, Ahmed, Kamoun, Aurélie, Marie, Yannick, Mokhtari, Karima, Tabouret, Emeline, Trabelsi, Nesrine, Uro-Coste, Emmanuelle, Delattre, Jean-Yves, Figarella-Branger, Dominique, POLA Network·2019·Neuro-Oncology

Abstract

Background: The 2016 WHO classification of the central nervous system tumors stratifies IDH-mutant gliomas into two major groups depending on the presence or absence of 1p/19q-codeletion. However, the grading system remains unchanged and it is now controversial whether it can be still applied to this updated molecular classification. Methods: In a large cohort of 911 high grade IDH-mutant gliomas from the French national POLA network (including 428 IDH-mutant gliomas without 1p/19q-codeletion and 483 anaplastic oligodendrogliomas, IDH-mutant and 1p/19q-codeleted), we investigated the prognostic value of CDKN2A gene homozygous deletion as well as WHO grading criteria (mitoses, microvascular proliferation and necrosis). In addition, we also searched for other retinoblastoma pathway gene alterations (CDK4 amplification and RB1 homozygous deletion) in a subset of patients. CDKN2A homozygous deletion was also searched in an independent series of 40 grade II IDH-mutant gliomas. Results: CDKN2A homozygous deletion was associated with dismal outcome among IDH-mutant gliomas lacking 1p/19q-codeletion (p<0.0001 for progression-free survival and p=0.004 for overall survival) as well as among anaplastic oligodendrogliomas, IDH-mutant and 1p/19q-codeleted (p=0.002 for progression-free survival and p<0.0001 for overall survival) in univariate and multivariate analysis including age, extend of surgery, adjuvant treatment, MVP and necrosis. In both groups, the presence of microvascular proliferation (MVP) and/or necrosis remained of prognostic value only in cases lacking CDKN2A homozygous deletion. CDKN2A homozygous deletion was not recorded in grade II gliomas. Conclusions: Our study pointed out the utmost relevance of CDKN2A homozygous deletion as an adverse prognostic factor in the two broad categories of IDH-mutant gliomas stratified on 1p/19q-codeletion and suggest to refine the grading of these tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/noz124

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 278

Metadata

Authors
Appay, R., Dehais, C., Maurage, C.-A., Alentorn, A., Carpentier, C., Colin, C., Ducray, F., Escande, F., Idbaih, A., Kamoun, A., Marie, Y., Mokhtari, K., Tabouret, E., Trabelsi, N., Uro-Coste, E., Delattre, J.-Y., Figarella-Branger, D., & POLA Network
Venue
Neuro-Oncology
Published
2019-07-12
Volume
21
Issue
12
Pages
1519-1528
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2956589719
Cited by
278
References
25
FWCI
12.73
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. https://app.cochat.ai/papers/10.1093/neuonc/noz124
The paper
Appay, R., Dehais, C., Maurage, C.-A., Alentorn, A., Carpentier, C., Colin, C., Ducray, F., Escande, F., Idbaih, A., Kamoun, A., Marie, Y., Mokhtari, K., Tabouret, E., Trabelsi, N., Uro-Coste, E., Delattre, J.-Y., Figarella-Branger, D., & POLA Network. (2019). CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro-Oncology. https://doi.org/10.1093/neuonc/noz124

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.